Edition:
United Kingdom

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

0.21USD
6:20pm GMT
Change (% chg)

$-0.01 (-2.41%)
Prev Close
$0.22
Open
$0.21
Day's High
$0.22
Day's Low
$0.20
Volume
44,582
Avg. Vol
129,024
52-wk High
$1.08
52-wk Low
$0.19

Chart for

About

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize,... (more)

Overall

Beta: 3.13
Market Cap(Mil.): $38.52
Shares Outstanding(Mil.): 100.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Bio Path Holdings Provides Clinical Update And 2018 Business Outlook

* BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2018 BUSINESS OUTLOOK

29 Dec 2017

BRIEF-Bio-Path Holdings Q3 loss per share $0.02

* Bio-Path Holdings reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Bio-Path Holdings announces $4 mln registered direct offering

* Bio-Path Holdings, Inc. Announces $4 million registered direct offering

03 Nov 2017

BRIEF-Bio Path Holdings receives notice of allowance for key U.S. composition of matter patent

* Bio Path Holdings - U.S. PTO has issued notice of allowance for claims related to co's liposomal delivery and antisense technology, dnabilize Source text for Eikon: Further company coverage:

19 Jul 2017

Competitors

Earnings vs. Estimates